SG&A Efficiency Analysis: Comparing AbbVie Inc. and Pharming Group N.V.

SG&A Efficiency: A Tale of Two Companies

In the competitive landscape of the pharmaceutical industry, understanding the efficiency of Selling, General, and Administrative (SG&A) expenses is crucial. Over the past decade, AbbVie Inc. and Pharming Group N.V. have showcased contrasting trajectories in their SG&A expenditures.

AbbVie Inc.: A Steady Climb

From 2014 to 2023, AbbVie Inc. has seen a significant increase in its SG&A expenses, peaking in 2022 with a 97% rise from 2014. This growth reflects AbbVie's strategic investments in marketing and administration to bolster its market presence.

Pharming Group N.V.: A Modest Rise

Conversely, Pharming Group N.V. experienced a more modest increase, with SG&A expenses growing by approximately 2,160% over the same period. Despite the smaller scale, this growth indicates Pharming's efforts to expand its footprint in the pharmaceutical sector.

These insights highlight the diverse strategies employed by pharmaceutical giants in managing operational costs.